Recognised Life Sciences and IP-driven innovation valuation experts.

Known for much more than the number.

Value What Matters!
Let alignment begin.

From the earliest idea to the exit — structuring financial yield across deals, board decisions, and audits.

"We need a number". The number is necessary. It is rarely sufficient.

Value has a trajectory. We read where it's heading.

It moves with the science, the team, the capital structure, and the decisions made in the board room and at the negotiating table — and it has to hold under audit.

Reading that trajectory with precision, independently of who is asking, is the work.

Boards question it. Investors price on it. Auditors sign off on it.

Twenty years spent inside the science, the deal terms, and the governance room — building the view that holds, wherever it's tested.

When that clarity exists, something shifts.

The investor reads science and management differently, the board elevate to its best and deals get done on terms that hold. Yield has a chance.

The investor perspective

You may be surprised by the importance we give to the investor perspective.

Science and capital rarely come from the same pocket

The breakthrough is one thing. Funding it — through early investors, VCs, family offices, or industrial partner — is another. The asset moves between them, and each reads it differently.

Understanding what yield requires

Valuing an asset is one skill. Understanding what each type of investor actually needs to say yes — their return logic, their expectation on optionality, their constraints — is another. Rarely found in the same place.

Making each side legible to the other

That is the intersection where we work: the science made legible to the capital that funds it, the capital logic made legible to the team that built it — so neither side goes unheard in a language that was never theirs to begin with.

Discover our financial and valuation services